Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis-Reference-Cited by-同舟云学术

Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis

Published:2022-01-06 Issue:4 Volume:36 Page:1180-1184
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Ravichandran Sriram^ORCID,Law Steven^ORCID,Mahmood Shameem,Wisniowski Brenden,Foard Darren,Fontana Marianna,Martinez-Naharro Ana,Whelan Carol,Gillmore Julian D.,Lachmann Helen J.,Hawkins Philip N.,Wechalekar Ashutosh D.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-021-01497-7.pdf

Reference15 articles.

1. Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and survival trends in amyloidosis, 1987-2019. N Engl J Med. 2020;382:1567–8.

2. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–9.

3. Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134:2271–80.

4. Godara A, Toskic D, Rosenthal B, Varga C, Kugelmass A, Zhou P, et al. In systemic light-chain amyloidosis complete and very good partial responses are not enough: involved free light chain (iFLC) levels < 10mg/L are associated with optimal long-term survival. Blood. 2019;134:4369–4369.

5. Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Impact of early relapse after auto-SCT for multiple Myeloma. Bone Marrow Transpl. 2008;42:413–20. 2008/09/01

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response matters in light chain amyloidosis, whatever it takes;British Journal of Haematology;2024-06-06

2. Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib‐based regime;British Journal of Haematology;2024-06-05

3. Risk factors, treatments and outcomes of patients with light chain amyloidosis who relapse after autologous stem cell transplantation;Bone Marrow Transplantation;2023-12-26

4. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment;American Journal of Hematology;2023-12-14

5. Peritoneal Amyloidosis as a Presenting Manifestation of AL Amyloid;Journal of Community Hospital Internal Medicine Perspectives;2023-05-10